Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Marek, Mraz"'
Autor:
Laura Ondrisova, Vaclav Seda, Eva Hoferkova, Giorgia Chiodin, Krystof Hlavac, Lenka Kostalova, Daniel Filip, Pedro Faria Zeni, Anna Panovska, Karla Plevova, Sarka Pospisilova, Martin Simkovic, Filip Vrbacky, Daniel Lysak, Stacey M. Fernandes, Matthew S. Davids, Alba Maiques-Diaz, Stella Charalampopoulou, Jose I Martin-Subero, Jennifer R Brown, Michael Doubek, Francesco Forconi, Jiri Mayer, Marek Mraz
Publikováno v:
HemaSphere, Vol 7, p e8228434 (2023)
Externí odkaz:
https://doaj.org/article/d170c389beac401f8b76921cc6daacb9
Autor:
Marek Mraz
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 14 (2022)
Externí odkaz:
https://doaj.org/article/59593a7bbf994ed881f2fd490f39a919
Autor:
Veronika Sandova, Gabriela Mladonicka Pavlasova, Vaclav Seda, Katerina Amruz Cerna, Sonali Sharma, Veronika Palusova, Yvona Brychtova, Sarka Pospisilova, Stacey M. Fernandes, Anna Panovska, Michael Doubek, Matthew S. Davids, Jennifer R. Brown, Jiri Mayer, Marek Mraz
Publikováno v:
Haematologica, Vol 106, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/e422b71f968242cc8640995049b46d0e
Publikováno v:
Cancers, Vol 14, Iss 13, p 3087 (2022)
T cells are key components in environments that support chronic lymphocytic leukemia (CLL), activating CLL-cell proliferation and survival. Here, we review in vitro and in vivo model systems that mimic CLL–T-cell interactions, since these are criti
Externí odkaz:
https://doaj.org/article/217f6f7574ba4261b894f7b36e8c6f43
Autor:
Laura Ondrisova, Marek Mraz
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
The approval of BTK and PI3K inhibitors (ibrutinib, idelalisib) represents a revolution in the therapy of B cell malignancies such as chronic lymphocytic leukemia (CLL), mantle-cell lymphoma (MCL), diffuse large B cell lymphoma (DLBCL), follicular ly
Externí odkaz:
https://doaj.org/article/c6cecb8b3540452ba0defdb80d94b24d
Autor:
Gabriela Pavlasova, Marek Mraz
Publikováno v:
Haematologica, Vol 105, Iss 6 (2020)
The introduction of anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, or obinutuzumab improved the therapy of B-cell malignancies even though the precise physiological role and regulation of CD20 remains unclear. Furthermore, CD20 expres
Externí odkaz:
https://doaj.org/article/b07ff56bd4a048cb8e3ab60ac890d38f
Autor:
Miroslav Boudny, Jana Zemanova, Prashant Khirsariya, Marek Borsky, Jan Verner, Jana Cerna, Alexandra Oltova, Vaclav Seda, Marek Mraz, Josef Jaros, Zuzana Jaskova, Michaela Spunarova, Yvona Brychtova, Karel Soucek, Stanislav Drapela, Marie Kasparkova, Jiri Mayer, Kamil Paruch, Martin Trbusek
Publikováno v:
Haematologica, Vol 104, Iss 12 (2019)
Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation
Externí odkaz:
https://doaj.org/article/e872ad7d936f40299c20d4bb02b9ef06
Autor:
Anna Schuh, Hélène Dreau, Andreas Heger, David Sims, Fritz Offner, Bruno Verhasselt, Jan Philippé, André Efira, Virginie De Wilde, Marie Maerevoet, Radu Firescu, Philippe Mineur, Nathalie Meuleman, Peter Hillmen, David Bruce, Adele Timbs, Adam Burns, Pauline Robbe, Marek Mraz, Ruth Clifford, Karlien Pieters, Emerence Crompot, Thomas Smith, Basile Stamatopoulos
Supplementary Data Table S1: general characterisctic of the different cohorts of patients Supplementary Data Table S2: characterisctic of Population A Supplementary Data Table S3: characterisctic of Population B Supplementary Data Table S4: character
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e8b6261612d72e47a04ba5cab498fb5
https://doi.org/10.1158/1078-0432.22474745
https://doi.org/10.1158/1078-0432.22474745
Autor:
Anna Schuh, Hélène Dreau, Andreas Heger, David Sims, Fritz Offner, Bruno Verhasselt, Jan Philippé, André Efira, Virginie De Wilde, Marie Maerevoet, Radu Firescu, Philippe Mineur, Nathalie Meuleman, Peter Hillmen, David Bruce, Adele Timbs, Adam Burns, Pauline Robbe, Marek Mraz, Ruth Clifford, Karlien Pieters, Emerence Crompot, Thomas Smith, Basile Stamatopoulos
Purpose: Unmutated (UM) immunoglobulin heavy chain variable region (IgHV) status or IgHV3-21 gene usage is associated with poor prognosis in chronic lymphocytic leukemia (CLL) patients. Interestingly, IgHV3-21 is often co-expressed with light chain I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57cdf1c245710e45d783276bd3991dd4
https://doi.org/10.1158/1078-0432.c.6528896.v1
https://doi.org/10.1158/1078-0432.c.6528896.v1
Autor:
Anna Schuh, Hélène Dreau, Andreas Heger, David Sims, Fritz Offner, Bruno Verhasselt, Jan Philippé, André Efira, Virginie De Wilde, Marie Maerevoet, Radu Firescu, Philippe Mineur, Nathalie Meuleman, Peter Hillmen, David Bruce, Adele Timbs, Adam Burns, Pauline Robbe, Marek Mraz, Ruth Clifford, Karlien Pieters, Emerence Crompot, Thomas Smith, Basile Stamatopoulos
Supplementary Data Figure S1. Determination of IgLV3-21 positivity by real-time PCR. Supplementary Data Figure S2: CLL-OS analysis including only CLL-related deaths. Supplementary Data Figure S3. Validation of the poor prognosis associated with IgLV3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c290abb945e53d972d785077c5b18f34
https://doi.org/10.1158/1078-0432.22474742
https://doi.org/10.1158/1078-0432.22474742